Emphysema Clinical Trial
Official title:
Characterizing Mmp12 In Sputum And Its Relationship To Emphysema And Inflammatory Endotypes
The hypothesis is that in patients with emphysema, a high MMP12 sputum and/or blood level correlates with airspace enlargement and with increased sputum Th2 immune biomarkers.
Since MMP-12 apparently has a preponderant role in the genesis of emphysema and probably in airspace enlargement, its inhibition may result in an interesting targeting point in view to find specific therapies in obstructive diseases. There is abundant evidence in animal models that shows how MMP-12 blockade inhibits the development of emphysema and airway remodeling. Unfortunately, the results have not been conclusive in human models. In the last years, pulmonary imaging biomarkers that measure airspace enlargement have been developed. In particular, the apparent diffusion coefficient (ADC), quantified by inhaled hyperpolarized gas MRI, reflects alveolar airspace size. ADC provides information consistent with histopathological findings that may be used to estimate lung disease progression and treatment response. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05825261 -
Exploring Novel Biomarkers for Emphysema Detection
|
||
| Completed |
NCT02999685 -
Home-based Health Management of Chronic Obstructive Lung Disease (COPD) Patients
|
N/A | |
| Completed |
NCT02914340 -
REACH SVS Control Patient Cross-Over Study
|
N/A | |
| Completed |
NCT02232841 -
Electrical Impedance Imaging of Patients on Mechanical Ventilation
|
N/A | |
| Completed |
NCT02238327 -
Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes
|
||
| Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
| Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
| Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
| Completed |
NCT01710449 -
Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen
|
Phase 1 | |
| Suspended |
NCT00523094 -
Vibration Response Imaging (VRI) in Patients That Are Candidates for Undergoing Pulmonary Operation Procedure
|
N/A | |
| Completed |
NCT00475007 -
Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema
|
N/A | |
| Recruiting |
NCT00129350 -
Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation
|
Phase 1 | |
| Completed |
NCT01953523 -
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
|
N/A | |
| Completed |
NCT00000621 -
Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)
|
Phase 2 | |
| Completed |
NCT00005292 -
Alpha1-antitrypsin Deficiency Registry
|
N/A | |
| Recruiting |
NCT04537182 -
Surgical Compared to Bronchoscopic Lung Volume Reduction in Patients With Severe Emphysema
|
N/A | |
| Active, not recruiting |
NCT02713347 -
Advancing Symptom Alleviation With Palliative Treatment
|
N/A | |
| Recruiting |
NCT04302272 -
STRIVE Post-Market Registry Study
|
||
| Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
| Completed |
NCT03636347 -
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
|
Phase 2 |